Anić Branimir, Grazio Simeon
Zavod za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb.
Reumatizam. 2006;53(2):63-5.
Recently, many studies showed need to administer vitamin D in treatment of osteoporosis. Vitamin D deficiency was proved in postmenopausal women with osteoporosis. Effects of vitamin D resulted in lower risk of fractures and falls, as well as improvement of neuromuscular performances. In more than ten years of practice and several short- and long-term clinical studies alendronate lowered the risk of vertebral and extravertebral fractures, improved BMD of all measured sites in postmenopausal women and men with osteoporosis. Positive results of alendronate were demonstrated in different entities like persons of various ages and grades of lower BMD or patients with glucocorticoid-induced osteoporosis. Combination of vitamin D with efficacious antiresorptive drug alendronate maintains all pharmacological features and proves clinical effects of lx weekly alendronate, partly eliminating need for vitamin D supplementation.
最近，许多研究表明在骨质疏松症治疗中需要补充维生素D。骨质疏松症的绝经后女性被证实存在维生素D缺乏。维生素D的作用包括降低骨折和跌倒风险，以及改善神经肌肉功能。在十多年的实践以及多项短期和长期临床研究中，阿仑膦酸盐降低了绝经后骨质疏松症女性和男性的椎体和非椎体骨折风险，提高了所有测量部位的骨密度。阿仑膦酸盐在不同人群中都显示出积极效果，如不同年龄、低骨密度程度各异的人群或糖皮质激素诱导的骨质疏松症患者。维生素D与有效的抗吸收药物阿仑膦酸盐联合使用保留了所有药理特性，并证明了每周一次阿仑膦酸盐的临床效果，部分消除了补充维生素D的必要性。
